nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—penis—urinary bladder cancer	0.0556	0.191	CbGeAlD
Lithium—IMPA2—prostate gland—urinary bladder cancer	0.0156	0.0536	CbGeAlD
Lithium—GSK3B—prostate gland—urinary bladder cancer	0.0153	0.0526	CbGeAlD
Lithium—IMPA1—renal system—urinary bladder cancer	0.0142	0.0487	CbGeAlD
Lithium—GSK3A—prostate gland—urinary bladder cancer	0.0133	0.0457	CbGeAlD
Lithium—IMPA2—seminal vesicle—urinary bladder cancer	0.0132	0.0453	CbGeAlD
Lithium—IMPA1—female reproductive system—urinary bladder cancer	0.0113	0.039	CbGeAlD
Lithium—GSK3A—seminal vesicle—urinary bladder cancer	0.0112	0.0387	CbGeAlD
Lithium—GSK3B—epithelium—urinary bladder cancer	0.0112	0.0386	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—urinary bladder cancer	0.0109	1	CbGdCrCtD
Lithium—GSK3B—smooth muscle tissue—urinary bladder cancer	0.0108	0.0372	CbGeAlD
Lithium—IMPA2—renal system—urinary bladder cancer	0.0106	0.0365	CbGeAlD
Lithium—IMPA2—urethra—urinary bladder cancer	0.0104	0.0359	CbGeAlD
Lithium—GSK3B—renal system—urinary bladder cancer	0.0104	0.0358	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—urinary bladder cancer	0.00941	0.0324	CbGeAlD
Lithium—GSK3A—renal system—urinary bladder cancer	0.00906	0.0312	CbGeAlD
Lithium—GSK3A—urethra—urinary bladder cancer	0.0089	0.0306	CbGeAlD
Lithium—IMPA2—female reproductive system—urinary bladder cancer	0.0085	0.0293	CbGeAlD
Lithium—GSK3B—female reproductive system—urinary bladder cancer	0.00834	0.0287	CbGeAlD
Lithium—IMPA2—vagina—urinary bladder cancer	0.00769	0.0265	CbGeAlD
Lithium—GSK3B—vagina—urinary bladder cancer	0.00755	0.026	CbGeAlD
Lithium—GSK3A—female reproductive system—urinary bladder cancer	0.00726	0.025	CbGeAlD
Lithium—GSK3A—vagina—urinary bladder cancer	0.00656	0.0226	CbGeAlD
Lithium—IMPA2—lymph node—urinary bladder cancer	0.00498	0.0171	CbGeAlD
Lithium—GSK3B—lymph node—urinary bladder cancer	0.00488	0.0168	CbGeAlD
Lithium—GSK3A—lymph node—urinary bladder cancer	0.00424	0.0146	CbGeAlD
Lithium—Vision blurred—Thiotepa—urinary bladder cancer	0.000685	0.0029	CcSEcCtD
Lithium—Coordination abnormal—Epirubicin—urinary bladder cancer	0.000681	0.00289	CcSEcCtD
Lithium—Oliguria—Doxorubicin—urinary bladder cancer	0.000672	0.00285	CcSEcCtD
Lithium—Agitation—Thiotepa—urinary bladder cancer	0.000668	0.00283	CcSEcCtD
Lithium—Bradycardia—Cisplatin—urinary bladder cancer	0.000666	0.00282	CcSEcCtD
Lithium—Dysarthria—Doxorubicin—urinary bladder cancer	0.000655	0.00277	CcSEcCtD
Lithium—Coma—Methotrexate—urinary bladder cancer	0.000653	0.00277	CcSEcCtD
Lithium—Salivary hypersecretion—Epirubicin—urinary bladder cancer	0.00065	0.00275	CcSEcCtD
Lithium—Urine output increased—Methotrexate—urinary bladder cancer	0.000646	0.00274	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—urinary bladder cancer	0.00063	0.00267	CcSEcCtD
Lithium—Convulsion—Thiotepa—urinary bladder cancer	0.000629	0.00267	CcSEcCtD
Lithium—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000627	0.00266	CcSEcCtD
Lithium—Alopecia—Gemcitabine—urinary bladder cancer	0.00062	0.00263	CcSEcCtD
Lithium—Arthralgia—Thiotepa—urinary bladder cancer	0.000618	0.00262	CcSEcCtD
Lithium—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000617	0.00261	CcSEcCtD
Lithium—Coma—Epirubicin—urinary bladder cancer	0.000611	0.00259	CcSEcCtD
Lithium—Tinnitus—Cisplatin—urinary bladder cancer	0.00061	0.00259	CcSEcCtD
Lithium—Alopecia—Fluorouracil—urinary bladder cancer	0.00061	0.00259	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—urinary bladder cancer	0.000601	0.00255	CcSEcCtD
Lithium—Confusional state—Thiotepa—urinary bladder cancer	0.000598	0.00253	CcSEcCtD
Lithium—Polyuria—Methotrexate—urinary bladder cancer	0.000591	0.00251	CcSEcCtD
Lithium—Hypertonia—Epirubicin—urinary bladder cancer	0.000586	0.00249	CcSEcCtD
Lithium—Arrhythmia—Cisplatin—urinary bladder cancer	0.000584	0.00248	CcSEcCtD
Lithium—Alopecia—Cisplatin—urinary bladder cancer	0.000578	0.00245	CcSEcCtD
Lithium—Vision blurred—Fluorouracil—urinary bladder cancer	0.000566	0.0024	CcSEcCtD
Lithium—Coma—Doxorubicin—urinary bladder cancer	0.000566	0.0024	CcSEcCtD
Lithium—Anorexia—Thiotepa—urinary bladder cancer	0.000565	0.0024	CcSEcCtD
Lithium—Flatulence—Cisplatin—urinary bladder cancer	0.000561	0.00238	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—urinary bladder cancer	0.000543	0.0023	CcSEcCtD
Lithium—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00054	0.00229	CcSEcCtD
Lithium—Vision blurred—Cisplatin—urinary bladder cancer	0.000537	0.00228	CcSEcCtD
Lithium—Tremor—Cisplatin—urinary bladder cancer	0.000534	0.00226	CcSEcCtD
Lithium—Alopecia—Etoposide—urinary bladder cancer	0.00053	0.00225	CcSEcCtD
Lithium—Lethargy—Methotrexate—urinary bladder cancer	0.00053	0.00225	CcSEcCtD
Lithium—Somnolence—Thiotepa—urinary bladder cancer	0.000527	0.00223	CcSEcCtD
Lithium—Dyspepsia—Thiotepa—urinary bladder cancer	0.000522	0.00221	CcSEcCtD
Lithium—Convulsion—Fluorouracil—urinary bladder cancer	0.000521	0.00221	CcSEcCtD
Lithium—Arthralgia—Gemcitabine—urinary bladder cancer	0.00052	0.00221	CcSEcCtD
Lithium—Decreased appetite—Thiotepa—urinary bladder cancer	0.000515	0.00218	CcSEcCtD
Lithium—Discomfort—Gemcitabine—urinary bladder cancer	0.000514	0.00218	CcSEcCtD
Lithium—Fatigue—Thiotepa—urinary bladder cancer	0.000511	0.00217	CcSEcCtD
Lithium—Dysgeusia—Etoposide—urinary bladder cancer	0.000511	0.00217	CcSEcCtD
Lithium—Discomfort—Fluorouracil—urinary bladder cancer	0.000505	0.00214	CcSEcCtD
Lithium—Oedema—Gemcitabine—urinary bladder cancer	0.000499	0.00211	CcSEcCtD
Lithium—Lethargy—Epirubicin—urinary bladder cancer	0.000496	0.0021	CcSEcCtD
Lithium—Confusional state—Fluorouracil—urinary bladder cancer	0.000494	0.0021	CcSEcCtD
Lithium—Convulsion—Cisplatin—urinary bladder cancer	0.000493	0.00209	CcSEcCtD
Lithium—Oedema—Fluorouracil—urinary bladder cancer	0.00049	0.00208	CcSEcCtD
Lithium—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000489	0.00207	CcSEcCtD
Lithium—Ataxia—Methotrexate—urinary bladder cancer	0.000488	0.00207	CcSEcCtD
Lithium—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000485	0.00206	CcSEcCtD
Lithium—Discomfort—Cisplatin—urinary bladder cancer	0.000479	0.00203	CcSEcCtD
Lithium—Anorexia—Gemcitabine—urinary bladder cancer	0.000475	0.00202	CcSEcCtD
Lithium—Vertigo—Etoposide—urinary bladder cancer	0.000469	0.00199	CcSEcCtD
Lithium—Body temperature increased—Thiotepa—urinary bladder cancer	0.000469	0.00199	CcSEcCtD
Lithium—Abdominal pain—Thiotepa—urinary bladder cancer	0.000469	0.00199	CcSEcCtD
Lithium—Anorexia—Fluorouracil—urinary bladder cancer	0.000467	0.00198	CcSEcCtD
Lithium—Hypotension—Gemcitabine—urinary bladder cancer	0.000466	0.00198	CcSEcCtD
Lithium—Oedema—Cisplatin—urinary bladder cancer	0.000465	0.00197	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—urinary bladder cancer	0.000459	0.00194	CcSEcCtD
Lithium—Lethargy—Doxorubicin—urinary bladder cancer	0.000459	0.00194	CcSEcCtD
Lithium—Hypotension—Fluorouracil—urinary bladder cancer	0.000458	0.00194	CcSEcCtD
Lithium—Ataxia—Epirubicin—urinary bladder cancer	0.000457	0.00194	CcSEcCtD
Lithium—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000454	0.00193	CcSEcCtD
Lithium—Convulsion—Etoposide—urinary bladder cancer	0.000452	0.00192	CcSEcCtD
Lithium—Dehydration—Epirubicin—urinary bladder cancer	0.000452	0.00191	CcSEcCtD
Lithium—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000447	0.00189	CcSEcCtD
Lithium—Dry skin—Epirubicin—urinary bladder cancer	0.000445	0.00189	CcSEcCtD
Lithium—Somnolence—Gemcitabine—urinary bladder cancer	0.000443	0.00188	CcSEcCtD
Lithium—Anorexia—Cisplatin—urinary bladder cancer	0.000443	0.00188	CcSEcCtD
Lithium—Discomfort—Etoposide—urinary bladder cancer	0.000439	0.00186	CcSEcCtD
Lithium—Somnolence—Fluorouracil—urinary bladder cancer	0.000436	0.00185	CcSEcCtD
Lithium—Hypotension—Cisplatin—urinary bladder cancer	0.000434	0.00184	CcSEcCtD
Lithium—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000434	0.00184	CcSEcCtD
Lithium—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000432	0.00183	CcSEcCtD
Lithium—Fatigue—Gemcitabine—urinary bladder cancer	0.00043	0.00182	CcSEcCtD
Lithium—Gastritis—Epirubicin—urinary bladder cancer	0.00043	0.00182	CcSEcCtD
Lithium—Confusional state—Etoposide—urinary bladder cancer	0.000429	0.00182	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—urinary bladder cancer	0.000428	0.00182	CcSEcCtD
Lithium—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000426	0.00181	CcSEcCtD
Lithium—Asthenia—Thiotepa—urinary bladder cancer	0.000425	0.0018	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000424	0.0018	CcSEcCtD
Lithium—Ataxia—Doxorubicin—urinary bladder cancer	0.000423	0.00179	CcSEcCtD
Lithium—Dehydration—Doxorubicin—urinary bladder cancer	0.000418	0.00177	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000413	0.00175	CcSEcCtD
Lithium—Dry skin—Doxorubicin—urinary bladder cancer	0.000412	0.00175	CcSEcCtD
Lithium—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000411	0.00174	CcSEcCtD
Lithium—Anorexia—Etoposide—urinary bladder cancer	0.000406	0.00172	CcSEcCtD
Lithium—Diarrhoea—Thiotepa—urinary bladder cancer	0.000406	0.00172	CcSEcCtD
Lithium—Decreased appetite—Cisplatin—urinary bladder cancer	0.000404	0.00171	CcSEcCtD
Lithium—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000404	0.00171	CcSEcCtD
Lithium—Drowsiness—Methotrexate—urinary bladder cancer	0.0004	0.0017	CcSEcCtD
Lithium—Hypotension—Etoposide—urinary bladder cancer	0.000398	0.00169	CcSEcCtD
Lithium—Gastritis—Doxorubicin—urinary bladder cancer	0.000398	0.00169	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000396	0.00168	CcSEcCtD
Lithium—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000394	0.00167	CcSEcCtD
Lithium—Dizziness—Thiotepa—urinary bladder cancer	0.000392	0.00166	CcSEcCtD
Lithium—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000388	0.00164	CcSEcCtD
Lithium—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000383	0.00162	CcSEcCtD
Lithium—Weight increased—Epirubicin—urinary bladder cancer	0.000382	0.00162	CcSEcCtD
Lithium—Weight decreased—Epirubicin—urinary bladder cancer	0.00038	0.00161	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000379	0.00161	CcSEcCtD
Lithium—Somnolence—Etoposide—urinary bladder cancer	0.000379	0.0016	CcSEcCtD
Lithium—Vomiting—Thiotepa—urinary bladder cancer	0.000377	0.0016	CcSEcCtD
Lithium—Drowsiness—Epirubicin—urinary bladder cancer	0.000374	0.00159	CcSEcCtD
Lithium—Rash—Thiotepa—urinary bladder cancer	0.000374	0.00158	CcSEcCtD
Lithium—Dermatitis—Thiotepa—urinary bladder cancer	0.000373	0.00158	CcSEcCtD
Lithium—Headache—Thiotepa—urinary bladder cancer	0.000371	0.00157	CcSEcCtD
Lithium—Decreased appetite—Etoposide—urinary bladder cancer	0.00037	0.00157	CcSEcCtD
Lithium—Body temperature increased—Cisplatin—urinary bladder cancer	0.000367	0.00156	CcSEcCtD
Lithium—Fatigue—Etoposide—urinary bladder cancer	0.000367	0.00156	CcSEcCtD
Lithium—Asthenia—Gemcitabine—urinary bladder cancer	0.000358	0.00152	CcSEcCtD
Lithium—Weight increased—Doxorubicin—urinary bladder cancer	0.000353	0.0015	CcSEcCtD
Lithium—Nausea—Thiotepa—urinary bladder cancer	0.000352	0.00149	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—urinary bladder cancer	0.000351	0.00149	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—urinary bladder cancer	0.000351	0.00149	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.00035	0.00149	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000348	0.00148	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—urinary bladder cancer	0.000346	0.00147	CcSEcCtD
Lithium—Bradycardia—Epirubicin—urinary bladder cancer	0.000342	0.00145	CcSEcCtD
Lithium—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000341	0.00145	CcSEcCtD
Lithium—Abdominal pain—Etoposide—urinary bladder cancer	0.000337	0.00143	CcSEcCtD
Lithium—Body temperature increased—Etoposide—urinary bladder cancer	0.000337	0.00143	CcSEcCtD
Lithium—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000336	0.00142	CcSEcCtD
Lithium—Tinnitus—Methotrexate—urinary bladder cancer	0.000335	0.00142	CcSEcCtD
Lithium—Asthenia—Cisplatin—urinary bladder cancer	0.000334	0.00141	CcSEcCtD
Lithium—Dizziness—Fluorouracil—urinary bladder cancer	0.000324	0.00137	CcSEcCtD
Lithium—Diarrhoea—Cisplatin—urinary bladder cancer	0.000318	0.00135	CcSEcCtD
Lithium—Alopecia—Methotrexate—urinary bladder cancer	0.000317	0.00134	CcSEcCtD
Lithium—Vomiting—Gemcitabine—urinary bladder cancer	0.000317	0.00134	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—urinary bladder cancer	0.000316	0.00134	CcSEcCtD
Lithium—Rash—Gemcitabine—urinary bladder cancer	0.000314	0.00133	CcSEcCtD
Lithium—Dermatitis—Gemcitabine—urinary bladder cancer	0.000314	0.00133	CcSEcCtD
Lithium—Tinnitus—Epirubicin—urinary bladder cancer	0.000313	0.00133	CcSEcCtD
Lithium—Headache—Gemcitabine—urinary bladder cancer	0.000312	0.00132	CcSEcCtD
Lithium—Vomiting—Fluorouracil—urinary bladder cancer	0.000312	0.00132	CcSEcCtD
Lithium—Rash—Fluorouracil—urinary bladder cancer	0.000309	0.00131	CcSEcCtD
Lithium—Dermatitis—Fluorouracil—urinary bladder cancer	0.000309	0.00131	CcSEcCtD
Lithium—Headache—Fluorouracil—urinary bladder cancer	0.000307	0.0013	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—urinary bladder cancer	0.000306	0.0013	CcSEcCtD
Lithium—Asthenia—Etoposide—urinary bladder cancer	0.000306	0.0013	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—urinary bladder cancer	0.0003	0.00127	CcSEcCtD
Lithium—Alopecia—Epirubicin—urinary bladder cancer	0.000297	0.00126	CcSEcCtD
Lithium—Nausea—Gemcitabine—urinary bladder cancer	0.000296	0.00126	CcSEcCtD
Lithium—Vomiting—Cisplatin—urinary bladder cancer	0.000296	0.00125	CcSEcCtD
Lithium—Vision blurred—Methotrexate—urinary bladder cancer	0.000295	0.00125	CcSEcCtD
Lithium—Rash—Cisplatin—urinary bladder cancer	0.000293	0.00124	CcSEcCtD
Lithium—Dermatitis—Cisplatin—urinary bladder cancer	0.000293	0.00124	CcSEcCtD
Lithium—Diarrhoea—Etoposide—urinary bladder cancer	0.000291	0.00124	CcSEcCtD
Lithium—Nausea—Fluorouracil—urinary bladder cancer	0.000291	0.00123	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—urinary bladder cancer	0.00029	0.00123	CcSEcCtD
Lithium—Flatulence—Epirubicin—urinary bladder cancer	0.000288	0.00122	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—urinary bladder cancer	0.000286	0.00121	CcSEcCtD
Lithium—Dizziness—Etoposide—urinary bladder cancer	0.000282	0.00119	CcSEcCtD
Lithium—Vertigo—Methotrexate—urinary bladder cancer	0.000281	0.00119	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000278	0.00118	CcSEcCtD
Lithium—Nausea—Cisplatin—urinary bladder cancer	0.000276	0.00117	CcSEcCtD
Lithium—Vision blurred—Epirubicin—urinary bladder cancer	0.000276	0.00117	CcSEcCtD
Lithium—Alopecia—Doxorubicin—urinary bladder cancer	0.000275	0.00116	CcSEcCtD
Lithium—Convulsion—Methotrexate—urinary bladder cancer	0.000271	0.00115	CcSEcCtD
Lithium—Vomiting—Etoposide—urinary bladder cancer	0.000271	0.00115	CcSEcCtD
Lithium—Agitation—Epirubicin—urinary bladder cancer	0.000269	0.00114	CcSEcCtD
Lithium—Rash—Etoposide—urinary bladder cancer	0.000269	0.00114	CcSEcCtD
Lithium—Dermatitis—Etoposide—urinary bladder cancer	0.000268	0.00114	CcSEcCtD
Lithium—Headache—Etoposide—urinary bladder cancer	0.000267	0.00113	CcSEcCtD
Lithium—Flatulence—Doxorubicin—urinary bladder cancer	0.000267	0.00113	CcSEcCtD
Lithium—Arthralgia—Methotrexate—urinary bladder cancer	0.000266	0.00113	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000265	0.00112	CcSEcCtD
Lithium—Discomfort—Methotrexate—urinary bladder cancer	0.000263	0.00111	CcSEcCtD
Lithium—Vertigo—Epirubicin—urinary bladder cancer	0.000263	0.00111	CcSEcCtD
Lithium—Syncope—Epirubicin—urinary bladder cancer	0.000262	0.00111	CcSEcCtD
Lithium—Confusional state—Methotrexate—urinary bladder cancer	0.000257	0.00109	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000257	0.00109	CcSEcCtD
Lithium—Vision blurred—Doxorubicin—urinary bladder cancer	0.000255	0.00108	CcSEcCtD
Lithium—Convulsion—Epirubicin—urinary bladder cancer	0.000253	0.00107	CcSEcCtD
Lithium—Nausea—Etoposide—urinary bladder cancer	0.000253	0.00107	CcSEcCtD
Lithium—Arthralgia—Epirubicin—urinary bladder cancer	0.000249	0.00106	CcSEcCtD
Lithium—Agitation—Doxorubicin—urinary bladder cancer	0.000249	0.00105	CcSEcCtD
Lithium—Discomfort—Epirubicin—urinary bladder cancer	0.000246	0.00104	CcSEcCtD
Lithium—Dry mouth—Epirubicin—urinary bladder cancer	0.000244	0.00103	CcSEcCtD
Lithium—Vertigo—Doxorubicin—urinary bladder cancer	0.000243	0.00103	CcSEcCtD
Lithium—Anorexia—Methotrexate—urinary bladder cancer	0.000243	0.00103	CcSEcCtD
Lithium—Syncope—Doxorubicin—urinary bladder cancer	0.000243	0.00103	CcSEcCtD
Lithium—Confusional state—Epirubicin—urinary bladder cancer	0.000241	0.00102	CcSEcCtD
Lithium—Oedema—Epirubicin—urinary bladder cancer	0.000239	0.00101	CcSEcCtD
Lithium—Hypotension—Methotrexate—urinary bladder cancer	0.000238	0.00101	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000238	0.00101	CcSEcCtD
Lithium—Shock—Epirubicin—urinary bladder cancer	0.000235	0.000996	CcSEcCtD
Lithium—Convulsion—Doxorubicin—urinary bladder cancer	0.000234	0.000994	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000232	0.000985	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—urinary bladder cancer	0.00023	0.000977	CcSEcCtD
Lithium—Discomfort—Doxorubicin—urinary bladder cancer	0.000228	0.000965	CcSEcCtD
Lithium—Anorexia—Epirubicin—urinary bladder cancer	0.000228	0.000965	CcSEcCtD
Lithium—Somnolence—Methotrexate—urinary bladder cancer	0.000227	0.000961	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—urinary bladder cancer	0.000225	0.000955	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—urinary bladder cancer	0.000225	0.000952	CcSEcCtD
Lithium—Hypotension—Epirubicin—urinary bladder cancer	0.000223	0.000946	CcSEcCtD
Lithium—Confusional state—Doxorubicin—urinary bladder cancer	0.000223	0.000944	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—urinary bladder cancer	0.000222	0.00094	CcSEcCtD
Lithium—Oedema—Doxorubicin—urinary bladder cancer	0.000221	0.000936	CcSEcCtD
Lithium—Fatigue—Methotrexate—urinary bladder cancer	0.00022	0.000932	CcSEcCtD
Lithium—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000217	0.000922	CcSEcCtD
Lithium—Shock—Doxorubicin—urinary bladder cancer	0.000217	0.000921	CcSEcCtD
Lithium—Somnolence—Epirubicin—urinary bladder cancer	0.000212	0.0009	CcSEcCtD
Lithium—Anorexia—Doxorubicin—urinary bladder cancer	0.000211	0.000893	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00021	0.000891	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—urinary bladder cancer	0.00021	0.000891	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000209	0.000884	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—urinary bladder cancer	0.000208	0.00088	CcSEcCtD
Lithium—Hypotension—Doxorubicin—urinary bladder cancer	0.000206	0.000875	CcSEcCtD
Lithium—Fatigue—Epirubicin—urinary bladder cancer	0.000206	0.000872	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—urinary bladder cancer	0.000202	0.000855	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—urinary bladder cancer	0.000202	0.000855	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000201	0.000853	CcSEcCtD
Lithium—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000197	0.000834	CcSEcCtD
Lithium—Somnolence—Doxorubicin—urinary bladder cancer	0.000196	0.000832	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000195	0.000827	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000194	0.000824	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000192	0.000814	CcSEcCtD
Lithium—Fatigue—Doxorubicin—urinary bladder cancer	0.00019	0.000807	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—urinary bladder cancer	0.000189	0.0008	CcSEcCtD
Lithium—Body temperature increased—Epirubicin—urinary bladder cancer	0.000189	0.0008	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—KRAS—urinary bladder cancer	0.000184	0.000397	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—urinary bladder cancer	0.000183	0.000776	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR—KRAS—urinary bladder cancer	0.000183	0.000395	CbGpPWpGaD
Lithium—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000182	0.000772	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—SRC—urinary bladder cancer	0.000182	0.000394	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KRAS—urinary bladder cancer	0.000182	0.000393	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—urinary bladder cancer	0.000181	0.000392	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KRAS—urinary bladder cancer	0.000181	0.000391	CbGpPWpGaD
Lithium—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000181	0.000766	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—urinary bladder cancer	0.00018	0.000389	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—urinary bladder cancer	0.00018	0.000389	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—urinary bladder cancer	0.00018	0.000389	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—urinary bladder cancer	0.000179	0.000388	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CXCL8—urinary bladder cancer	0.000179	0.000387	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—EP300—urinary bladder cancer	0.000179	0.000387	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—urinary bladder cancer	0.000179	0.000386	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—urinary bladder cancer	0.000178	0.000385	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—urinary bladder cancer	0.000177	0.000383	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—urinary bladder cancer	0.000177	0.000383	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HDAC4—urinary bladder cancer	0.000176	0.000381	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—urinary bladder cancer	0.000176	0.000381	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—RHOA—urinary bladder cancer	0.000176	0.000381	CbGpPWpGaD
Lithium—GSK3A—Disease—JAG1—urinary bladder cancer	0.000175	0.000378	CbGpPWpGaD
Lithium—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000175	0.00074	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000175	0.00074	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—urinary bladder cancer	0.000175	0.00074	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—urinary bladder cancer	0.000173	0.000375	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	0.000173	0.000375	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—EP300—urinary bladder cancer	0.000173	0.000374	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—RHOA—urinary bladder cancer	0.000173	0.000374	CbGpPWpGaD
Lithium—Asthenia—Epirubicin—urinary bladder cancer	0.000171	0.000726	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000171	0.000369	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—urinary bladder cancer	0.00017	0.000368	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—urinary bladder cancer	0.00017	0.000368	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—urinary bladder cancer	0.00017	0.000368	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—urinary bladder cancer	0.00017	0.000368	CbGpPWpGaD
Lithium—Dizziness—Methotrexate—urinary bladder cancer	0.000169	0.000715	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—KRAS—urinary bladder cancer	0.000169	0.000365	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—urinary bladder cancer	0.000167	0.000361	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—urinary bladder cancer	0.000167	0.00036	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—urinary bladder cancer	0.000166	0.00036	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—urinary bladder cancer	0.000166	0.000359	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—urinary bladder cancer	0.000166	0.000359	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—urinary bladder cancer	0.000163	0.000353	CbGpPWpGaD
Lithium—Diarrhoea—Epirubicin—urinary bladder cancer	0.000163	0.000692	CcSEcCtD
Lithium—GSK3A—Innate Immune System—CREBBP—urinary bladder cancer	0.000163	0.000353	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNA2—urinary bladder cancer	0.000162	0.000351	CbGpPWpGaD
Lithium—Vomiting—Methotrexate—urinary bladder cancer	0.000162	0.000688	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—CDKN1A—urinary bladder cancer	0.000161	0.000349	CbGpPWpGaD
Lithium—Rash—Methotrexate—urinary bladder cancer	0.000161	0.000682	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—EP300—urinary bladder cancer	0.000161	0.000348	CbGpPWpGaD
Lithium—Dermatitis—Methotrexate—urinary bladder cancer	0.000161	0.000681	CcSEcCtD
Lithium—GSK3B—Axon guidance—ERBB2—urinary bladder cancer	0.00016	0.000346	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—urinary bladder cancer	0.00016	0.000346	CbGpPWpGaD
Lithium—Headache—Methotrexate—urinary bladder cancer	0.00016	0.000677	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	0.00016	0.000345	CbGpPWpGaD
Lithium—Asthenia—Doxorubicin—urinary bladder cancer	0.000158	0.000672	CcSEcCtD
Lithium—Dizziness—Epirubicin—urinary bladder cancer	0.000158	0.000669	CcSEcCtD
Lithium—GSK3B—B Cell Activation—KRAS—urinary bladder cancer	0.000157	0.00034	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—urinary bladder cancer	0.000157	0.000339	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—urinary bladder cancer	0.000157	0.000339	CbGpPWpGaD
Lithium—GSK3B—Immune System—RBX1—urinary bladder cancer	0.000157	0.000338	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CDK4—urinary bladder cancer	0.000156	0.000338	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTEN—urinary bladder cancer	0.000156	0.000338	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—urinary bladder cancer	0.000156	0.000337	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—urinary bladder cancer	0.000156	0.000337	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDH1—urinary bladder cancer	0.000156	0.000336	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—urinary bladder cancer	0.000155	0.000336	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—urinary bladder cancer	0.000154	0.000334	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—urinary bladder cancer	0.000154	0.000332	CbGpPWpGaD
Lithium—GSK3A—Immune System—S100B—urinary bladder cancer	0.000154	0.000332	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—EP300—urinary bladder cancer	0.000153	0.000332	CbGpPWpGaD
Lithium—GSK3B—Disease—ENO2—urinary bladder cancer	0.000152	0.00033	CbGpPWpGaD
Lithium—Vomiting—Epirubicin—urinary bladder cancer	0.000152	0.000643	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—urinary bladder cancer	0.000152	0.000328	CbGpPWpGaD
Lithium—Nausea—Methotrexate—urinary bladder cancer	0.000152	0.000642	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—CDKN1A—urinary bladder cancer	0.000151	0.000327	CbGpPWpGaD
Lithium—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000151	0.000641	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—PTEN—urinary bladder cancer	0.000151	0.000326	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—urinary bladder cancer	0.000151	0.000326	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	0.000151	0.000326	CbGpPWpGaD
Lithium—Rash—Epirubicin—urinary bladder cancer	0.000151	0.000638	CcSEcCtD
Lithium—Dermatitis—Epirubicin—urinary bladder cancer	0.00015	0.000637	CcSEcCtD
Lithium—Headache—Epirubicin—urinary bladder cancer	0.00015	0.000634	CcSEcCtD
Lithium—IMPA2—Metabolism—EP300—urinary bladder cancer	0.000149	0.000322	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLI1—urinary bladder cancer	0.000148	0.000319	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—urinary bladder cancer	0.000146	0.000619	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—urinary bladder cancer	0.000145	0.000313	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—urinary bladder cancer	0.000145	0.000313	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—urinary bladder cancer	0.000145	0.000313	CbGpPWpGaD
Lithium—GSK3B—Disease—RBX1—urinary bladder cancer	0.000144	0.000312	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—urinary bladder cancer	0.000143	0.00031	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PPARG—urinary bladder cancer	0.000142	0.000307	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	0.000142	0.000307	CbGpPWpGaD
Lithium—Nausea—Epirubicin—urinary bladder cancer	0.000142	0.000601	CcSEcCtD
Lithium—GSK3B—Innate Immune System—FGFR3—urinary bladder cancer	0.000142	0.000306	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—urinary bladder cancer	0.000141	0.000306	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—IGF1—urinary bladder cancer	0.000141	0.000304	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—urinary bladder cancer	0.00014	0.000595	CcSEcCtD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—urinary bladder cancer	0.00014	0.000303	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—SRC—urinary bladder cancer	0.00014	0.000303	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTEN—urinary bladder cancer	0.000139	0.000301	CbGpPWpGaD
Lithium—Rash—Doxorubicin—urinary bladder cancer	0.000139	0.00059	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—urinary bladder cancer	0.000139	0.00059	CcSEcCtD
Lithium—Headache—Doxorubicin—urinary bladder cancer	0.000138	0.000587	CcSEcCtD
Lithium—GSK3B—Axon guidance—MMP9—urinary bladder cancer	0.000137	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RBX1—urinary bladder cancer	0.000137	0.000296	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—urinary bladder cancer	0.000137	0.000295	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—urinary bladder cancer	0.000137	0.000295	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—urinary bladder cancer	0.000137	0.000295	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CREBBP—urinary bladder cancer	0.000137	0.000295	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FGFR3—urinary bladder cancer	0.000136	0.000294	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—urinary bladder cancer	0.000134	0.000289	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—urinary bladder cancer	0.000133	0.000288	CbGpPWpGaD
Lithium—IMPA1—Metabolism—EP300—urinary bladder cancer	0.000133	0.000287	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—EP300—urinary bladder cancer	0.000133	0.000287	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—urinary bladder cancer	0.000131	0.000284	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—urinary bladder cancer	0.000131	0.000556	CcSEcCtD
Lithium—GSK3B—Disease—JAG1—urinary bladder cancer	0.000129	0.00028	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSC1—urinary bladder cancer	0.000129	0.000278	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	0.000128	0.000277	CbGpPWpGaD
Lithium—GSK3A—Disease—NCOR1—urinary bladder cancer	0.000127	0.000276	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—SRC—urinary bladder cancer	0.000127	0.000274	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RHOA—urinary bladder cancer	0.000123	0.000267	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—urinary bladder cancer	0.000123	0.000265	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JAG1—urinary bladder cancer	0.000123	0.000265	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CREBBP—urinary bladder cancer	0.000121	0.000261	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNA2—urinary bladder cancer	0.00012	0.000259	CbGpPWpGaD
Lithium—GSK3A—Disease—ERCC2—urinary bladder cancer	0.00012	0.000259	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1A—urinary bladder cancer	0.000117	0.000253	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—urinary bladder cancer	0.000117	0.000252	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—urinary bladder cancer	0.000116	0.000251	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—urinary bladder cancer	0.000116	0.00025	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDH1—urinary bladder cancer	0.000115	0.000248	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—urinary bladder cancer	0.000114	0.000247	CbGpPWpGaD
Lithium—GSK3B—Immune System—S100B—urinary bladder cancer	0.000113	0.000245	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000113	0.000245	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—urinary bladder cancer	0.000113	0.000244	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—urinary bladder cancer	0.000112	0.000243	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000112	0.000242	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—urinary bladder cancer	0.000112	0.000242	CbGpPWpGaD
Lithium—GSK3A—Immune System—FGFR3—urinary bladder cancer	0.000112	0.000241	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EP300—urinary bladder cancer	0.000111	0.00024	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—urinary bladder cancer	0.000111	0.00024	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—urinary bladder cancer	0.00011	0.000237	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SRC—urinary bladder cancer	0.000108	0.000234	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—urinary bladder cancer	0.000105	0.000227	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SRC—urinary bladder cancer	0.000104	0.000224	CbGpPWpGaD
Lithium—GSK3A—Disease—FGFR3—urinary bladder cancer	0.000103	0.000223	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RBX1—urinary bladder cancer	0.000101	0.000219	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—urinary bladder cancer	0.000101	0.000218	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—S100B—urinary bladder cancer	9.92e-05	0.000215	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—urinary bladder cancer	9.85e-05	0.000213	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—urinary bladder cancer	9.81e-05	0.000212	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—urinary bladder cancer	9.7e-05	0.00021	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSC1—urinary bladder cancer	9.51e-05	0.000206	CbGpPWpGaD
Lithium—GSK3A—Immune System—CREBBP—urinary bladder cancer	9.5e-05	0.000205	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—urinary bladder cancer	9.47e-05	0.000205	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDH1—urinary bladder cancer	9.43e-05	0.000204	CbGpPWpGaD
Lithium—GSK3B—Disease—NCOR1—urinary bladder cancer	9.42e-05	0.000204	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EP300—urinary bladder cancer	9.3e-05	0.000201	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—urinary bladder cancer	9.09e-05	0.000197	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JAG1—urinary bladder cancer	9.06e-05	0.000196	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SRC—urinary bladder cancer	9.04e-05	0.000195	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—urinary bladder cancer	8.95e-05	0.000193	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NCOR1—urinary bladder cancer	8.92e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—urinary bladder cancer	8.92e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Disease—ERCC2—urinary bladder cancer	8.85e-05	0.000191	CbGpPWpGaD
Lithium—GSK3A—Disease—CREBBP—urinary bladder cancer	8.77e-05	0.00019	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1A—urinary bladder cancer	8.63e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—urinary bladder cancer	8.61e-05	0.000186	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—urinary bladder cancer	8.59e-05	0.000186	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—urinary bladder cancer	8.32e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—urinary bladder cancer	8.3e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1A—urinary bladder cancer	8.29e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—urinary bladder cancer	8.27e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Immune System—FGFR3—urinary bladder cancer	8.25e-05	0.000178	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EP300—urinary bladder cancer	8.21e-05	0.000178	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—urinary bladder cancer	7.98e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—urinary bladder cancer	7.96e-05	0.000172	CbGpPWpGaD
Lithium—GSK3A—Disease—RHOA—urinary bladder cancer	7.94e-05	0.000172	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—urinary bladder cancer	7.92e-05	0.000171	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—urinary bladder cancer	7.86e-05	0.00017	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—urinary bladder cancer	7.67e-05	0.000166	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR3—urinary bladder cancer	7.62e-05	0.000165	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—urinary bladder cancer	7.6e-05	0.000164	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—urinary bladder cancer	7.55e-05	0.000163	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—urinary bladder cancer	7.49e-05	0.000162	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—urinary bladder cancer	7.35e-05	0.000159	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—S100B—urinary bladder cancer	7.33e-05	0.000159	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—urinary bladder cancer	7.3e-05	0.000158	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FGFR3—urinary bladder cancer	7.22e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—urinary bladder cancer	7.21e-05	0.000156	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—urinary bladder cancer	7.18e-05	0.000155	CbGpPWpGaD
Lithium—GSK3B—Immune System—CREBBP—urinary bladder cancer	7.02e-05	0.000152	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ESR1—urinary bladder cancer	7.01e-05	0.000152	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—urinary bladder cancer	7e-05	0.000151	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDH1—urinary bladder cancer	6.97e-05	0.000151	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1A—urinary bladder cancer	6.8e-05	0.000147	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—urinary bladder cancer	6.79e-05	0.000147	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—urinary bladder cancer	6.72e-05	0.000145	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—urinary bladder cancer	6.61e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NCOR1—urinary bladder cancer	6.59e-05	0.000143	CbGpPWpGaD
Lithium—GSK3B—Disease—CREBBP—urinary bladder cancer	6.48e-05	0.00014	CbGpPWpGaD
Lithium—GSK3A—Immune System—EP300—urinary bladder cancer	6.47e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—urinary bladder cancer	6.36e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—urinary bladder cancer	6.35e-05	0.000137	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—urinary bladder cancer	6.29e-05	0.000136	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1A—urinary bladder cancer	6.28e-05	0.000136	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—urinary bladder cancer	6.27e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CREBBP—urinary bladder cancer	6.14e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1—urinary bladder cancer	6.07e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Disease—EP300—urinary bladder cancer	5.98e-05	0.000129	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—urinary bladder cancer	5.88e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Disease—RHOA—urinary bladder cancer	5.87e-05	0.000127	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—urinary bladder cancer	5.81e-05	0.000126	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—urinary bladder cancer	5.81e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—urinary bladder cancer	5.62e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RHOA—urinary bladder cancer	5.56e-05	0.00012	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—urinary bladder cancer	5.52e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—urinary bladder cancer	5.43e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—urinary bladder cancer	5.4e-05	0.000117	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FGFR3—urinary bladder cancer	5.33e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—urinary bladder cancer	5.33e-05	0.000115	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—urinary bladder cancer	5.31e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—urinary bladder cancer	5.21e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—urinary bladder cancer	5.21e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ESR1—urinary bladder cancer	5.18e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—urinary bladder cancer	5.15e-05	0.000111	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—urinary bladder cancer	5.09e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1A—urinary bladder cancer	5.03e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—urinary bladder cancer	5.01e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—urinary bladder cancer	4.88e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—urinary bladder cancer	4.81e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Immune System—EP300—urinary bladder cancer	4.78e-05	0.000103	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—urinary bladder cancer	4.66e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—urinary bladder cancer	4.65e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1A—urinary bladder cancer	4.64e-05	0.0001	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—urinary bladder cancer	4.63e-05	0.0001	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—urinary bladder cancer	4.55e-05	9.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CREBBP—urinary bladder cancer	4.54e-05	9.82e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1—urinary bladder cancer	4.48e-05	9.69e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—urinary bladder cancer	4.43e-05	9.58e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EP300—urinary bladder cancer	4.42e-05	9.55e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—urinary bladder cancer	4.41e-05	9.54e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1A—urinary bladder cancer	4.4e-05	9.51e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—urinary bladder cancer	4.39e-05	9.49e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—urinary bladder cancer	4.29e-05	9.28e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EP300—urinary bladder cancer	4.18e-05	9.05e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RHOA—urinary bladder cancer	4.11e-05	8.88e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—urinary bladder cancer	4.09e-05	8.84e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—urinary bladder cancer	4.08e-05	8.81e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—urinary bladder cancer	4.07e-05	8.8e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—urinary bladder cancer	3.85e-05	8.33e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—urinary bladder cancer	3.85e-05	8.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—urinary bladder cancer	3.8e-05	8.22e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—urinary bladder cancer	3.76e-05	8.14e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—urinary bladder cancer	3.65e-05	7.88e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—urinary bladder cancer	3.61e-05	7.8e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—urinary bladder cancer	3.57e-05	7.71e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—urinary bladder cancer	3.56e-05	7.69e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—urinary bladder cancer	3.45e-05	7.45e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—urinary bladder cancer	3.37e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—urinary bladder cancer	3.36e-05	7.26e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—urinary bladder cancer	3.27e-05	7.08e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—urinary bladder cancer	3.26e-05	7.05e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.25e-05	7.03e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—urinary bladder cancer	3.24e-05	7.01e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EP300—urinary bladder cancer	3.09e-05	6.69e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—urinary bladder cancer	3.02e-05	6.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—urinary bladder cancer	3.01e-05	6.5e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—urinary bladder cancer	2.99e-05	6.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—urinary bladder cancer	2.86e-05	6.19e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—urinary bladder cancer	2.69e-05	5.83e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—urinary bladder cancer	2.64e-05	5.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—urinary bladder cancer	2.49e-05	5.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—urinary bladder cancer	2.21e-05	4.78e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—urinary bladder cancer	2.12e-05	4.58e-05	CbGpPWpGaD
